Vireo Growth (VREOF) Cash & Equivalents Growth (1y) (2021 - 2026)
Vireo Growth (VREOF) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | -39.02% |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 120.45% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 12.78% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 50.32% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -32.64% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 138.97% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 37.30% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -12.11% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 59.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.86% |
| Dec 31, 2025 | 33.73% |
| Sep 30, 2025 | 1,514.58% |
| Jun 30, 2025 | 782.82% |
| Mar 31, 2025 | 583.92% |
| Dec 31, 2024 | 473.77% |
| Sep 30, 2024 | -45.25% |
| Jun 30, 2024 | -1.03% |
| Mar 31, 2024 | 21.83% |
| Dec 31, 2023 | 5.38% |
| Sep 30, 2023 | -39.13% |
| Jun 30, 2023 | -33.14% |
| Mar 31, 2023 | 20.28% |
| Dec 31, 2022 | -0.04% |
| Sep 30, 2022 | 85.43% |
| Jun 30, 2022 | -18.51% |
| Mar 31, 2022 | -78.79% |
| Dec 31, 2021 | -44.09% |
| Sep 30, 2021 | -34.10% |
| Jun 30, 2021 | 184.54% |